Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients

Table 1 Clinical characteristics of 83 patients with arthroscopy

Variables	Total	ACPA positive	ACPA negative	P value
Variables	Number = 83	Number = 64	Number = 19	P value
Sex (Female%)	62	64	58	0.62
Age at arthroscopy (Mean, SD)	55.98 ± 12.7	55.29 ± 12.8	58.23 ± 12.3	0.47
Disease duration to arthroscopy (Median, IQR 25 to 75) months	45.50 (10.8–122.1)	34.56 (8.8–122.0)	79.0 (15.1–126.8)	0.27
Rheumatoid factor (%)	78	87	47	<0.001*
Extra-articular disease (%)	31	35	20	0.28
Erosive disease (%)	74	72	76	0.73
CRP mg/dl (Median, IQR 25 to 75)	2.32 (1.0–5.3)	2.95 (1.0–5.9)	1.43 (0.7–3.7)	0.21
ESR mm (Median, IQR 25 to 75)	32 (16.0– 64.0)	37 (17.5–70.0)	26 (14.7–39)	0.07
DAS28 (Median, IQR 25 to 75)	4.74 (3.6–5.5)	4.81 (3.7–5.5)	4.74 (3.2–5.5)	0.52
mHAQ (Median, IQR 25 to 75)	1.19 (0.5–1.5)	1.25 (0.6–1.6)	0.56 (0.2–0.7)	0.10
Number of DMARDs (ever), Mean (SD)	2.20 (1.1)	2.20 (1.1)	1.86 (1.1)	0.89
Methotrexate (%), ever	88.4	88.9	88.7	0.98
Biologic treatment (%, before arthroscopy) ever	40.6	40.0	42.0	0.85

ACPA, anti citrullinated peptide/protein antibodies; CRP, C-reactive protein; DAS-28, disease activity score -28 joints; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; IQR, interquartile range; mHAQ, Modified Health Assessment Questionnaire, SD, standard deviation; SJC, swelling joint count; TJC, tender joint count. *p value is significant if <0.05.

ISSN: 1478-6362